Elevance Health (NYSE:ELV – Get Free Report) was upgraded by investment analysts at Argus from a “hold” rating to a “buy” rating in a report released on Wednesday, Marketbeat.com reports. The brokerage currently has a $510.00 price objective on the stock. Argus‘s target price would suggest a potential upside of 30.47% from the company’s previous close.
Several other analysts also recently weighed in on ELV. Mizuho set a $490.00 price objective on shares of Elevance Health in a research report on Friday, October 23rd. Royal Bank Of Canada increased their target price on shares of Elevance Health from $424.00 to $455.00 and gave the company a “sector perform” rating in a research report on Thursday, October 22nd. Guggenheim increased their target price on shares of Elevance Health from $460.00 to $485.00 and gave the company a “buy” rating in a research report on Thursday, October 22nd. The Goldman Sachs Group reiterated a “neutral” rating and set a $451.00 price target on shares of Elevance Health in a research note on Friday, October 23rd. Finally, Wells Fargo & Company boosted their price target on shares of Elevance Health from $473.00 to $492.00 and gave the company an “overweight” rating in a research report on Tuesday, October 27th. Sixteen investment analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $458.91.
Get Our Latest Stock Report on ELV
Elevance Health Price Performance
Elevance Health (NYSE:ELV – Get Free Report) last announced its quarterly earnings results on Wednesday, October 21st. The company reported $6.99 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.71 by $2.28. The firm had revenue of $50.44 billion during the quarter, compared to the consensus estimate of $49.28 billion. Elevance Health had a return on equity of 14.97% and a net margin of 2.55%. The firm’s quarterly revenue was up .7% compared to the same quarter last year. During the same period in the prior year, the company posted $6.03 earnings per share. As a group, equities research analysts forecast that Elevance Health will post 29.16 EPS for the current fiscal year.
Insider Buying and Selling at Elevance Health
In other Elevance Health news, EVP Ratnakar Lavu sold 1,300 shares of the business’s stock in a transaction on Thursday, November 5th. The shares were sold at an average price of $440.00, for a total value of $572,000.00. Following the transaction, the executive vice president directly owned 14,849 shares of the company’s stock, valued at approximately $6,533,560. The trade was a 8.05% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Mark Kaye sold 10,584 shares of the company’s stock in a transaction on Thursday, October 22nd. The stock was sold at an average price of $440.13, for a total transaction of $4,658,335.92. Following the transaction, the chief financial officer owned 19,919 shares of the company’s stock, valued at approximately $8,766,949.47. The trade was a 34.70% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.34% of the stock is owned by company insiders.
Institutional Trading of Elevance Health
Hedge funds and other institutional investors have recently made changes to their positions in the company. Activest Wealth Management increased its stake in shares of Elevance Health by 146.2% during the 3rd quarter. Activest Wealth Management now owns 64 shares of the company’s stock worth $25,000 after purchasing an additional 38 shares in the last quarter. Clal Insurance Enterprises Holdings Ltd acquired a new position in shares of Elevance Health during the 3rd quarter worth approximately $26,000. WealthCollab LLC lifted its stake in Elevance Health by 42.2% in the 1st quarter. WealthCollab LLC now owns 91 shares of the company’s stock valued at $27,000 after buying an additional 27 shares in the last quarter. Kilter Group LLC purchased a new stake in Elevance Health in the 2nd quarter valued at approximately $28,000. Finally, Elevation Wealth Partners LLC grew its holdings in Elevance Health by 600.0% during the 2nd quarter. Elevation Wealth Partners LLC now owns 105 shares of the company’s stock valued at $41,000 after buying an additional 90 shares during the last quarter. Hedge funds and other institutional investors own 89.24% of the company’s stock.
Elevance Health Company Profile
Elevance Health, Inc. is a U.S. health benefits and services company. Formerly known as Anthem, Inc., it adopted the Elevance Health name in 2022 while retaining the Anthem brand for many of its health plans. The company offers medical, pharmacy, dental, vision and behavioral health coverage, including plans for individuals and employers as well as programs serving Medicare and Medicaid members. Its services also include care management, pharmacy benefit services and other health-related capabilities through its Carelon business.
Further Reading
- Five stocks we like better than Elevance Health
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Elevance Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevance Health and related companies with MarketBeat.com's FREE daily email newsletter.
